Vilobelimab in combination with tocilizumab may synergistically improve mortality in critically ill COVID-19 patients: a post-hoc analysis of the Phase III PANAMO study

Post-hoc analysis of the Phase III PANAMO study examining vilobelimab combined with tocilizumab in critically ill COVID-19 patients.

Publication · 2024-10-27

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

All white papers, case studies, publications and blogs.

Peer-reviewed and journal articles.

Talk to a senior contact about the work behind this.